Company news
Nfl Biosciences Sa (EURONEXT:ALNFL) news
Nfl Biosciences Sa news releases on 6ix. Latest, Oct 6, 2026: NFL Biosciences: Progress Update Ahead of Upcoming Value-Creating Milestones for Its Two…
Press releases & updates
NFL Biosciences: Progress Update Ahead of Upcoming Value-Creating Milestones for Its Two Clinical Programs in Smoking Cessation
October 6, 2026
NFL Biosciences to Present Its Personalized Medicine Approach to Smoking Cessation at the 20th Congress of the Société Francophone de Tabacologie
September 8, 2026
NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation
July 28, 2026
International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102
July 7, 2026
NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain
June 30, 2026
NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation
June 1, 2026
NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application
May 25, 2026
NFL Biosciences Clarifies the Objectives and Evaluation Criteria for a Predictive Biomarker Associated With NFL-101
May 11, 2026
NFL Biosciences: International Scientific Community’s Interest in NFL-102 for Smoking Cessation Confirmed by the Selection of Its Work at Two Leading Conferences
May 4, 2026
NFL Biosciences Presents Its 2025 Annual Results and Provides an Update on Its Clinical Progress Driven by a New Paradigm in Smoking Cessation
April 15, 2026
NFL Biosciences Strengthens Its Cash Position by €2.6 Million Through Bond Financing Subscribed by a Group of European Institutional Investors
April 15, 2026
A New Paradigm in Tobacco and Nicotine Addiction: NFL Biosciences Demonstrates the Mechanism of Action of NFL-102 in a Video
April 7, 2026
Bpifrance Renews Its Confidence in NFL Biosciences Through the Granting of a €500,000 Loan
March 11, 2026
NFL Biosciences Publishes Its 2026 Financial Agenda
February 19, 2026
NFL Biosciences Significantly Raises Its Efficacy Targets for Smoking Cessation
January 26, 2026
NFL Biosciences Obtains Complementary Characterization Results for NFL-101, its first-in-class Drug Candidate for Smoking Cessation, and Prepares a New Patent Application
December 8, 2025
NFL Biosciences Presents the Agenda for Results Expected by Regulatory Agencies and Potential Pharmaceutical Partners
November 12, 2025
NFL Biosciences Outlines Its Development Plan for NFL-101 in Smoking Cessation Following Receipt of Scientific Advice From Several European Agencies and the U.S. FDA
October 20, 2025
NFL Biosciences Reports Its 2025 Half-Year Results and Provides an Update on Its Development
October 16, 2025
NFL Biosciences Announces the Publication of the Results of Its Phase II Clinical Trial CESTO II Evaluating NFL-101 in Smoking Cessation in Nicotine & Tobacco Research, the Official Journal of the Society for Research on Nicotine and Tobacco (SRNT)
September 1, 2025
NFL Biosciences Announces a Scientific Collaboration with McLean Hospital (Boston, USA) to Further Investigate the Mechanism of Action of NFL-101
July 28, 2025
NFL Biosciences Secures Initial Non-Dilutive Funding of €1.2 Million, Adding to Its Recent Capital Increase, to Advance the Development of NFL-101, Its First-in-Class Treatment for Tobacco Addiction
July 22, 2025
NFL Biosciences : strengthens its clinical leadership by expanding Dr. Yannick Plétan’s role as Chief Medical Officer as part of the acceleration of its clinical development program for NFL-101 in smoking cessation
July 3, 2025
NFL Biosciences : announces the success of its capital increase capped at €3 million
May 23, 2025
NFL Biosciences : launches a capital increase of approximately €2.2 million
May 22, 2025
NFL Biosciences : strengthens its scientific committee with world-class experts to support the Phase 3 development of NFL-101, its first-in-class therapy for tobacco addiction
May 12, 2025
NFL Biosciences : announces results from a new study conducted with the CEA providing further insight into the effects of NFL-101, its first-in-class treatment for tobacco addiction, and highlighting its prolonged activity
May 5, 2025
NFL Biosciences : Marex Group initiates coverage of NFL Biosciences with a Buy rating
April 24, 2025